The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.

@article{Liby2006TheCO,
  title={The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.},
  author={Karen T. Liby and Mara H. Rendi and Nanjoo Suh and Darlene B. Royce and Renee Risingsong and Charlotte R. Williams and William W. Lamph and Fernand Labrie and Stan Stanislaw Krajewski and Xiaochun Xu and Heetae Kim and Powel Brown and Michael B. Sporn},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2006},
  volume={12 19},
  pages={5902-9}
}
PURPOSE We tested whether a selective estrogen receptor modulator (SERM) and a rexinoid are active for prevention and treatment in the mouse mammary tumor virus-neu mouse model of estrogen receptor-negative breast cancer. EXPERIMENTAL DESIGN For prevention, mice were fed a powdered control diet, the SERM arzoxifene (Arz, 20 mg/kg diet), the rexinoid… CONTINUE READING